Purchase this article with an account.
Erick Hernandez-Bogantes, Andrew Olivo-Payne, Alexandra Abdala, Juan Carlos Serna-Ojeda, Enrique O Graue-Hernandez, Alejandro Navas, Arturo J Ramirez-Miranda; Topical Interferon Alpha-2b In Giant Squamous Ocular Surface Neoplasia. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3895.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report a case series of 8 patients clinically diagnosed with giant ocular squamous neoplasia (OSSN) who underwent medical therapy with topical interferon alpha-2b for immunoreduction and immutherapy purposes
Patients received monthly dosis of topical interferon alpha-2b (1 million IU/mL) for a total of 3 months or with a subconjunctival injection (3 million IU/mL) single dose per week monthly until tumor resolution.
A total of eight eyes of 8 patients (mean age of 69 y/o) with a clinical diagnosis of unilateral giant OSSN were managed with interferon alpha-2b. Six patients received topical therapy (1 million IU/mL) 4 times per day for a minimum of 3 months for immunotherapeutic purposes and 2 patients received subconjunctival therapy (3 million IU/mL) single dose per week for 1 month for immunoreduction. The median time to resolution was 5 months (range, 1.5-6 months) and the median follow-up was 22 months (range, 6-28 months). Despite the dramatic clinical response, all patients continued with topical interferon alpha-2b at least 1 month beyond complete clinical resolution. The two cases in which immunoreduction was successfully achieved, were scheduled for a lesion excision with a no-touch technique followed by cryotherapy and amniotic membrane to cover the large excision area. There has been no recurrence during follow-up.
In cases of giant OSSN interferon alpha-2b can successfully reduce or achieve complete resolution, thus avoiding the patient a more extensive surgical procedure with its known risks and complications.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only